Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been […]
Subscribe and get notified about new posts.
Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system […]
A Global Community
It is in moments like this that we are reminded of the collective power of good to overcome the disenfranchised and of the incredible impact of even the smallest gestures to shape the course of history.
Staying Human in the Age of Artificial Intelligence
No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely […]
Making R&D ‘Smarter’ by Putting Artificial Intelligence into Practice
The pharmaceutical industry still faces unrelenting challenges across the entirety of the drug development landscape. According to Piper Sandler’s recent […]
Hitting the Spot
Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion of capital will enable HotSpot to transition into a clinical stage company while supporting further pipeline and platform growth.
Immuno-Oncology: The Comeback Kid
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.
Reimagining the Workplace Post Pandemic
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace
The Business of Science
Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a […]
